• Je něco špatně v tomto záznamu ?

Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer

W. Fukuokaya, K. Mori, T. Yanagisawa, F. Urabe, P. Rajwa, A. Briganti, SF. Shariat, N. Matsubara, T. Kimura, A. Hirakawa

. 2025 ; 131 (7) : e35819. [pub] 20250401

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009312

BACKGROUND: Investigation remains incomplete regarding potential variations in the effect of androgen receptor pathway inhibitors, including apalutamide, based on baseline tumor burden in patients with metastatic castration-sensitive prostate cancer (mCSPC). METHODS: The authors analyzed individual participant-level data from 1052 patients with mCSPC who were randomized in the TITAN trial (apalutamide vs. placebo, both with androgen-deprivation therapy). Outcomes included radiographic progression-free survival (PFS), second PFS (PFS2), and overall survival (OS). Multivariable Cox proportional hazards regression models, with and without restricted cubic splines, were used to determine the association between apalutamide benefit and bone metastasis count or visceral metastasis. Subgroup treatment effects were quantified based on inverse probability of treatment weighting-adjusted hazard ratios (HRs). RESULTS: Analysis using restricted cubic splines indicated that apalutamide provided less benefit for PFS2 and OS in patients with fewer bone metastases. The authors also found evidence of a heterogeneous effect of apalutamide on PFS2 and OS between patients with two or less bone metastases and those with three or more bone metastases. In patients who had two or less bone metastases, there was no evidence of a benefit from apalutamide for radiographic PFS (HR, 0.65; 95% confidence interval [CI], 0.35-1.22), PFS2 (HR, 1.18; 95% CI, 0.66-2.12), or OS (HR, 1.05; 95% CI, 0.60-1.83). No evidence of an association was noted between visceral metastasis and apalutamide benefit. CONCLUSIONS: The addition of apalutamide to androgen-deprivation therapy may provide less benefit in patients with mCSPC who have fewer bone metastases. Counting baseline bone metastases may help identify optimal candidates for apalutamide treatment of mCSPC. CLINICAL TRIALS REGISTRATION: NCT02489318 PLAIN LANGUAGE SUMMARY: In an analysis of individual participant data from a trial (the TITAN trial) in patients with metastatic (spreading) castration-sensitive prostate cancer, treatment intensification based on the addition new drugs to standard androgen-deprivation therapy (ADT) was analyzed and compared with the effects in patients who received only standard ADT. Compared with ADT alone, the survival benefit of adding the new drug apalutamide to standard ADT varied according to the number of bone metastases, but no association was observed between the spread of cancer to soft tissues and organs and a survival benefit from adding apalutamide. The results indicate that counting the number of bone metastases may help identify which patients with metastatic castration-sensitive prostate cancer are optimal candidates for treatment intensification with the addition of apalutamide to standard ADT.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009312
003      
CZ-PrNML
005      
20250429134525.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cncr.35819 $2 doi
035    __
$a (PubMed)40106307
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fukuokaya, Wataru $u Department of Clinical Biostatistics, Institute of Science Tokyo, Tokyo, Japan $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
245    10
$a Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer / $c W. Fukuokaya, K. Mori, T. Yanagisawa, F. Urabe, P. Rajwa, A. Briganti, SF. Shariat, N. Matsubara, T. Kimura, A. Hirakawa
520    9_
$a BACKGROUND: Investigation remains incomplete regarding potential variations in the effect of androgen receptor pathway inhibitors, including apalutamide, based on baseline tumor burden in patients with metastatic castration-sensitive prostate cancer (mCSPC). METHODS: The authors analyzed individual participant-level data from 1052 patients with mCSPC who were randomized in the TITAN trial (apalutamide vs. placebo, both with androgen-deprivation therapy). Outcomes included radiographic progression-free survival (PFS), second PFS (PFS2), and overall survival (OS). Multivariable Cox proportional hazards regression models, with and without restricted cubic splines, were used to determine the association between apalutamide benefit and bone metastasis count or visceral metastasis. Subgroup treatment effects were quantified based on inverse probability of treatment weighting-adjusted hazard ratios (HRs). RESULTS: Analysis using restricted cubic splines indicated that apalutamide provided less benefit for PFS2 and OS in patients with fewer bone metastases. The authors also found evidence of a heterogeneous effect of apalutamide on PFS2 and OS between patients with two or less bone metastases and those with three or more bone metastases. In patients who had two or less bone metastases, there was no evidence of a benefit from apalutamide for radiographic PFS (HR, 0.65; 95% confidence interval [CI], 0.35-1.22), PFS2 (HR, 1.18; 95% CI, 0.66-2.12), or OS (HR, 1.05; 95% CI, 0.60-1.83). No evidence of an association was noted between visceral metastasis and apalutamide benefit. CONCLUSIONS: The addition of apalutamide to androgen-deprivation therapy may provide less benefit in patients with mCSPC who have fewer bone metastases. Counting baseline bone metastases may help identify optimal candidates for apalutamide treatment of mCSPC. CLINICAL TRIALS REGISTRATION: NCT02489318 PLAIN LANGUAGE SUMMARY: In an analysis of individual participant data from a trial (the TITAN trial) in patients with metastatic (spreading) castration-sensitive prostate cancer, treatment intensification based on the addition new drugs to standard androgen-deprivation therapy (ADT) was analyzed and compared with the effects in patients who received only standard ADT. Compared with ADT alone, the survival benefit of adding the new drug apalutamide to standard ADT varied according to the number of bone metastases, but no association was observed between the spread of cancer to soft tissues and organs and a survival benefit from adding apalutamide. The results indicate that counting the number of bone metastases may help identify which patients with metastatic castration-sensitive prostate cancer are optimal candidates for treatment intensification with the addition of apalutamide to standard ADT.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a thiohydantoiny $x terapeutické užití $x aplikace a dávkování $7 D013867
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    12
$a tumor burden $x účinky léků $7 D047368
650    _2
$a nádory prostaty rezistentní na kastraci $x farmakoterapie $x patologie $x mortalita $7 D064129
650    _2
$a nádory kostí $x sekundární $x farmakoterapie $7 D001859
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a antagonisté androgenních receptorů $x terapeutické užití $7 D059002
650    _2
$a antagonisté androgenů $x terapeutické užití $7 D000726
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a metastázy nádorů $7 D009362
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Mori, Keiichiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Yanagisawa, Takafumi $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000274100712
700    1_
$a Urabe, Fumihiko $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Rajwa, Pawel $u Second Department of Urology, Center of Postgraduate Medical Education, Warsaw, Poland $u Division of Surgery and Interventional Science, University College London, London, UK $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Briganti, Alberto $u Department of Urology, Vita-Salute San Raffaele University, Milan, Italy
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, New York, USA $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Matsubara, Nobuaki $u Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan
700    1_
$a Kimura, Takahiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Hirakawa, Akihiro $u Department of Clinical Biostatistics, Institute of Science Tokyo, Tokyo, Japan
773    0_
$w MED00001031 $t Cancer $x 1097-0142 $g Roč. 131, č. 7 (2025), s. e35819
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40106307 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134521 $b ABA008
999    __
$a ok $b bmc $g 2310969 $s 1246393
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 131 $c 7 $d e35819 $e 20250401 $i 1097-0142 $m Cancer $n Cancer $x MED00001031
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace